
Community oncology significantly reduces cancer care costs while maintaining quality, offering a sustainable solution to financial toxicity for patients.

Community oncology significantly reduces cancer care costs while maintaining quality, offering a sustainable solution to financial toxicity for patients.

Lucio N. Gordan discusses the economic burden of financial toxicity in oncology, highlighting its impact on patients and the healthcare system.

Explore the complexities of interpreting clinical trial results versus real-world experiences in chronic GVHD treatment options.

Explore effective third-line treatments for chronic GVHD, focusing on the latest FDA-approved therapies and their impact on patient outcomes.

Rebecca Siegel, MPH, reveals key insights on lung cancer trends, survival rates, and the need for targeted interventions in diverse populations.

This segment examines optimal care for patients with early-stage non–small cell lung cancer (NSCLC) relying on coordinated multidisciplinary collaboration.

This case examines effective management of early-stage non–small cell lung cancer (NSCLC) requiring integrating imaging, laboratory results, and molecular profiling to guide therapy.

Explore the complexities of HPV status in head and neck cancer treatment, emphasizing the importance of accurate patient selection and evidence-based practices.

Experts discuss a virtual collaborative care model that integrates mental health support into oncology, enhancing patient care and improving treatment outcomes.

Leyla O. Shune, MD, discusses results from an interim safety analysis of a randomized phase 2 study exploring axatilimab in combination with ruxolitinib in patients with newly diagnosed chronic graft-versus-host disease.

Explore effective management strategies for chronic graft-versus-host disease, focusing on transitioning from steroids to second-line therapies like ruxolitinib.

A patient with chronic graft-versus-host disease faces treatment challenges, highlighting the need for effective management strategies post-transplant.

Jason S. Starr, DO, discusses his approach to dose reduction of cabozantinib in patients with neuroendocrine tumors.

Researchers explore the impact of virtual collaborative care on mental health and quality of life for breast cancer patients, revealing significant improvements.

Experts explore a virtual collaborative care model to enhance mental health support for breast cancer patients, aiming to improve treatment adherence and outcomes.

A 62-year-old woman with stage IIIA lung cancer faces complex diagnostic and treatment decisions, highlighting the importance of multidisciplinary evaluation.

New findings reveal promising advancements in treating relapsed mantle cell lymphoma with BCL-2 inhibitors and novel agents, enhancing patient outcomes.

Experts discuss the underutilization of biomarker testing in metastatic lung cancer, emphasizing the need for improved testing strategies and healthcare access.



Ramez N. Eskander, MD, discusses the optimal use of lenvatinib/pembrolizumab in clinical practice for patients with endometrial cancer. He provides advice for integrating this regimen into the treatment paradigm.

Real-world data reinforces the efficacy and tolerability of lenvatinib and pembrolizumab for treating recurring endometrial cancer.

In this final segment, Dr Luskin discusses treatment sequencing considerations in blastic plasmacytoid dendritic cell neoplasm (BPDCN), with a focus on integrating targeted therapy and allogeneic stem cell transplantation.

Recent studies highlight the effectiveness of lenvatinib and pembrolizumab in improving overall survival for patients with prior therapy in endometrial cancer.

This segment addresses the clinical implications of disease burden in blastic plasmacytoid dendritic cell neoplasm (BPDCN), a condition that frequently presents with extensive skin involvement or other high-burden manifestations.

Leyla O. Shune, MD, discusses an expanded access program in the United States that administered axatilimab to patients with chronic graft-versus-host disease. Specifically, she highlights the tolerability of axatilimab in the real-world setting.

Endometrial cancer treatment evolves with molecular insights, enhancing patient outcomes through tailored therapies and innovative clinical trials.

Research on myeloma shows significant progress in treatment options, emphasizing the need for early detection and access to care for affected communities.

Giredestrant shows lower treatment discontinuation rates compared to standard therapy and is being explored in combination with other drugs.

A recent study reveals promising results for CLL patients using zanubrutinib and venetoclax, highlighting effective time-limited therapy options.